Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Cyril Šálek"'
Autor:
Šárka Šestáková, Cyril Šálek, Dávid Kundrát, Ela Cerovská, Jan Vydra, Ivana Ježíšková, Adam Folta, Jiří Mayer, Petr Cetkovský, Hana Remešová
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with prognosis. However, studies integrating these numerous and potentially prognosti
Externí odkaz:
https://doaj.org/article/445a337be93740f6998ac1681e644cb8
Autor:
Kateřina Kuželová, Barbora Brodská, Jana Marková, Martina Petráčková, Johannes Schetelig, Šárka Ransdorfová, Zdenka Gašová, Cyril Šálek
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected marker
Externí odkaz:
https://doaj.org/article/4ab2548210ad4b5ab7f7e51955cc9c58
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of 28 different entities. Most of these malignancies are aggressive with rather poor
Externí odkaz:
https://doaj.org/article/b4d8795b61a74be087361df571256e0e
Autor:
Kateřina Kuželová, Barbora Brodská, Johannes Schetelig, Christoph Röllig, Zdeněk Ráčil, Juliane Stickel Walz, Grzegorz Helbig, Ota Fuchs, Milena Vraná, Pavla Pecherková, Cyril Šálek, Jiří Mayer
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0204290 (2018)
Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involv
Externí odkaz:
https://doaj.org/article/3fd95a99fad445768830ce05db5a447a
Autor:
Štěpán Hrabovský, Cyril Šálek, Pavla Pecherkova, Petr Cetkovský, Hana Jelínková, Eva Froňková, František Folber, Michael Doubek, Jiří Mayer, Jan Trka, Jan M. Horáček
Publikováno v:
British Journal of Haematology. 196:706-710
The aim of the present study was to evaluate the significance of low-level minimal/measurable residual disease (MRD) during early consolidation treatment in adult BCR-ABL1-negative acute lymphoblastic leukaemia. The MRD load was monitored by immunogl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc6c60c5dbdc66fb92c90784b37990a
https://doi.org/10.1111/bjh.17966
https://doi.org/10.1111/bjh.17966
Autor:
Hana Zizkova, Cyril Šálek, Katerina Machova Polakova, Adela Benesova, Hana Klamova, Nikola Curik, Eliska Motlova, Vaclava Polivkova, Jitka Koblihova
Publikováno v:
Leukemia. 35:2419-2423
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d9d60c8c71edc93ca293093fd764c03
https://doi.org/10.1038/s41375-021-01226-0
https://doi.org/10.1038/s41375-021-01226-0
Autor:
František Folber, Cyril Šálek, Jan M. Horáček, Jiri Mayer, Michael Doubek, Jiri Stika, Stepan Hrabovsky, Zuzana Vrzalová, Šárka Pospíšilová, Hana Jelínková, Veronika Navrkalová, Marie Jarošová, Jiri Martenek
Publikováno v:
Acta Oncologica. 60:760-770
BCR-ABL1-like acute lymphoblastic leukemia (ALL) is a high-risk disease with a complex genomic background. Though extensively studied, data on the frequency and mutual associations of present mutat...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65387698768f2e4126503ab9b1ee7fa2
https://doi.org/10.1080/0284186x.2021.1900908
https://doi.org/10.1080/0284186x.2021.1900908
Autor:
Šárka Šestáková, Ela Cerovská, Cyril Šálek, Dávid Kundrát, Ivana Ježíšková, Adam Folta, Jiří Mayer, Zdeněk Ráčil, Petr Cetkovský, Hana Remešová
Publikováno v:
Clinical Epigenetics. 14
Background Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358870f48ae6776368c9e1820c81e0e1
https://doi.org/10.1186/s13148-022-01242-6
https://doi.org/10.1186/s13148-022-01242-6
Autor:
Michal Kolář, Petr Cetkovský, Cyril Šálek, Marketa Markova, Milena Vrana, L. Nováková, Veronika Valkova, Robert Pytlik, Petr Lesný, Jan Vydra, Barbora Čemusová, Antonin Vitek, Petr Soukup
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:365-371
Introduction Survival rate of patients with chemorefractory acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB) is poor. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d81e1de8c35a93ddd7ed998b2654054
https://doi.org/10.1016/j.clml.2019.02.005
https://doi.org/10.1016/j.clml.2019.02.005
Autor:
Petr Cetkovský, Šárka Šestáková, Hana Remešová, Cyril Šálek, Zdeněk Krejčík, Zdeněk Ráčil, Pavla Pecherkova, Adam Folta, Jiří Mayer, Michaela Dostalova Merkerova, Ela Cerovska
Publikováno v:
Cancer Biomarkers. 25:43-51
Background Aberrant epigenetic patterns are a hallmark of acute myeloid leukemia (AML). Mutations in profound epigenetic regulators DNMT3A and IDH1/2 often occur concurrently in AML. Objectives The aim was to analyze DNA methylation, hydroxymethylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8126606a0d916d6db3a2b2984deea376
https://doi.org/10.3233/cbm-182176
https://doi.org/10.3233/cbm-182176